Association of cytotoxic T-lymphocyte antigen 4 genetic polymorphism, hepatitis C viral infection and B-cell non-Hodgkin lymphoma: An Egyptian study

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 1061-1066

  Khorshied, Mervat Mamdooh ^a   Gouda, Heba Mahmoud ^a   Khorshid, Ola M Reda ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

B NHL; CTLA 4; Egypt; Genetic polymorphism; HCV

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADULT; ADULT DISEASE; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DENATURATION; EGYPT; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEPATITIS C; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUTANT; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; ALLELE; B CELL LYMPHOMA; CANCER STAGING; CASE CONTROL STUDY; COMPLICATION; EXON; GENETIC POLYMORPHISM; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; CTLA-4 ANTIGEN; EGYPT; EXONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPATITIS C; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84899723363     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.820294     Document Type: Article

References (32)

1. Song H, Tong D, Cha Z, et a l. C-X-C chemokine receptor type 5 gene polymorphisms are associated with non-Hodgkin lymphoma. Mol Biol Rep 2012; 39: 8629-8635.
2. Muller AM, Ihorst G, Mertelsmann R, et al. Epidemiology of non-Hodgkin's lymphoma (NHL): Trends, geographic distribution, and etiology. Ann Hematol 2005; 84: 1-12.
3. Skibola C F, Curry J D, Nieters A. G enetic susceptibility to lymphoma. Haematologica 2007; 92: 960-969.
4. Alexander DD, Mink PJ, Adami H, et al. The non-Hodgkin lymphomas: A review of the epidemiologic literature. Int J Cancer 2007; 120: 1-39.
5. Monne M, Piras G, Palmas A, et al. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma. Am J Hematol 2004; 76: 14-18.
6. Egen J G, Kuhns M S, Allison J P. C TLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 611-618.
7. Appleman LJ, Berezovskaya A, Grass I, et al. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol 2002; 164: 144-151.
8. Scheipers P, Reiser H. F as-independent death of activated CD4 (-) T lymphocytes induced by CTLA-4 crosslinking. Proc Natl Acad Sci USA 1998; 95: 10083-10088.
9. Puré E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nat Immunol 2005; 6: 1207-1210.
10. Vandenborre K, Van Gool SW, Kasran A, et al. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology 1999; 98: 413-421.
11. Sun T, Zhou Y, Yang M, et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008; 68: 7025-7034.
12. Danilovic DL, Mendes-Correa MC, Lima EU, et al. Correlations of CTLA-4 gene polymorphisms and hepatitis C chronic infection. Liver Int 2012; 32: 803-808.
13. Arcaini L, Merli M, Volpetti S, et al. Indolent B-cell lymphomas associated with HCV infection: Clinical and virological features and role of antiviral therapy. Clin Dev Immunol 2012; 2012: 638185.
14. Varma S, Menon MC, Garg A, et al. Hepatitis C virus infection among patients with non-Hodgkin's 453 lymphoma in northern India. Hepatol Int 2011; 5: 688-692.
15. Farawela H, Khorshied M, Shaheen I, et a l. The association between hepatitis C virus infection, genetic polymorphisms of oxidative stress genes and B-cell non-Hodgkin's lymphoma risk in Egypt. Infect Genet Evol 2012; 12: 1189-1194.
16. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: Epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011; 117: 1792-1798.
17. Suarez F, Lortholary O, Hermine O, et al. Infection-Associated lymphomas derived from marginal zone B cells: A model of antigendriven lymphoproliferation. Blood 2006; 107: 3034-3044.
18. Hermine O, Lefrè r e F, Bronowicki J P, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 11:347: 89-94.
19. De Re V, Caggiari L, Garziera M, et al. Molecular signature in HCVpositive lymphomas. Clin Dev Immunol 2012; 2012: 623465.
20. Yee LJ, Perez KA, Tang J, et al. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 2003; 187: 1264-1271.
21. Nischalke HD, Vogel M, Mauss S, et al. The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(-) patients with acute and chronic hepatitis C virus coinfection . AIDS 2010; 24, 24:2001-2007.
22. Schott E, Witt H, Pascu M, et al. Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. Eur J Gastroenterol Hepatol 2007; 19: 947-951.
23. Cowgill K, Loff redo C, Eissa S, et al. Case control study of non-Hodgkin's lymphoma and hepatitis C virus infection in Egypt. Int J Epidemiol 2004; 33: 1034-1039.
24. Goldman L, Ezzat S, Mokhtar N, et al. Viral and non-viral risk factors for non-Hodgkin's lymphoma in Egypt: Heterogeneity by histological and immunological subtypes. Cancer Causes Control 2009; 20: 981-987.
25. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon; IARC Press; 2008.
26. Lister TA, Crowther D, Sutcliff e SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
27. Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005; 55: 368-376.
28. Ban Y, Davies T F, Greenberg D A, et a l. A nalysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease. Genes Immun 2003; 4: 586-593.
29. Ahmed S, Ihara K, Kanemistu S, et al. Association of CTLA-4 but not CD28 gene polymorphisms with systemic lupus erythematosis in the Japanese population. Rheumatology 2001; 40: 662-667.
30. Abo El-Khair SM, Metwali AA, Abd El-Maksoud M, et al. CTLA-4 gene polymorphism in relation to thyroid disorders in patients with chronic hepatitis C under interferon alpha therapy. Am J Biochem Biotechnol 2012; 8: 172-187.
31. Piras G, Monne M, Uras A, et al. Genetic analysis of the 2q33 region containing CD28-CTLA4-ICOS genes: Association with non-Hodgkin's lymphoma. Br J Haematol 2005; 129: 784-790.
32. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.